Feasibility of percutaneous excision followed by ablation for local control in breast cancer

Vicki Klimberg, Cristiano Boneti, Laura L. Adkins, Maureen Smith, Eric Siegel, Vladimir Zharov, Scott Ferguson, Ronda Henry-Tillman, Brian Badgwell, Soheila Korourian

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: Percutaneous ablation of breast cancer has shown promise as a treatment alternative to open lumpectomy. We hypothesized that percutaneous removal of breast cancer followed by percutaneous ablation to sterilize and widen the margins would not only provide fresh naive tissue for tumor marker and research investigation, but also better achieve negative margins after ablation. Methods: Patients diagnosed by percutaneous biopsy (ultrasound or stereotactic-guided) with breast cancer ≥1.5 cm,>1 cm from the skin, and ≤1 cm residual disease and no multicentric disease by magnetic resonance imaging were accrued to this institutional review board-approved study. Patients were randomized to laser versus radiofrequency ablation. The ultrasound-guided ablation was performed in the operating room and followed by immediate excision, whole-mount pathology with proliferating cell nuclear antigen staining, and reconstruction. Results: Twenty-one patients were enrolled onto the study. Fifteen patients received radiofrequency ablation, and all showed 100% ablation and negative margins. Magnetic resonance imaging was helpful in excluding multicentric disease but less so in predicting presence or absence of residual disease. Seven of these patients showed no residual tumor and eight showed residual dead tumor (0.5 ± 0.7 cm, range 0.1-2.5 cm) at the biopsy site with clear margins. The laser arm (3 patients) pathology demonstrated unpredictability of the ablation zone and residual live tumor. Conclusions: This pilot study demonstrates the feasibility of a novel approach to minimally invasive therapy: percutaneous excision and effective cytoreduction, followed by radiofrequency ablation of margins for the treatment of breast cancer. Laser treatment requires further improvement.

Original languageEnglish (US)
Pages (from-to)3079-3087
Number of pages9
JournalAnnals of Surgical Oncology
Volume18
Issue number11
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Breast Neoplasms
Residual Neoplasm
Lasers
Magnetic Resonance Imaging
Pathology
Biopsy
Segmental Mastectomy
Research Ethics Committees
Proliferating Cell Nuclear Antigen
Operating Rooms
Therapeutics
Tumor Biomarkers
Staining and Labeling
Skin
Research

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Feasibility of percutaneous excision followed by ablation for local control in breast cancer. / Klimberg, Vicki; Boneti, Cristiano; Adkins, Laura L.; Smith, Maureen; Siegel, Eric; Zharov, Vladimir; Ferguson, Scott; Henry-Tillman, Ronda; Badgwell, Brian; Korourian, Soheila.

In: Annals of Surgical Oncology, Vol. 18, No. 11, 10.2011, p. 3079-3087.

Research output: Contribution to journalArticle

Klimberg, V, Boneti, C, Adkins, LL, Smith, M, Siegel, E, Zharov, V, Ferguson, S, Henry-Tillman, R, Badgwell, B & Korourian, S 2011, 'Feasibility of percutaneous excision followed by ablation for local control in breast cancer', Annals of Surgical Oncology, vol. 18, no. 11, pp. 3079-3087. https://doi.org/10.1245/s10434-011-2002-y
Klimberg, Vicki ; Boneti, Cristiano ; Adkins, Laura L. ; Smith, Maureen ; Siegel, Eric ; Zharov, Vladimir ; Ferguson, Scott ; Henry-Tillman, Ronda ; Badgwell, Brian ; Korourian, Soheila. / Feasibility of percutaneous excision followed by ablation for local control in breast cancer. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 11. pp. 3079-3087.
@article{a2b6835eba0e496d9a032ffd6c5e695a,
title = "Feasibility of percutaneous excision followed by ablation for local control in breast cancer",
abstract = "Purpose: Percutaneous ablation of breast cancer has shown promise as a treatment alternative to open lumpectomy. We hypothesized that percutaneous removal of breast cancer followed by percutaneous ablation to sterilize and widen the margins would not only provide fresh naive tissue for tumor marker and research investigation, but also better achieve negative margins after ablation. Methods: Patients diagnosed by percutaneous biopsy (ultrasound or stereotactic-guided) with breast cancer ≥1.5 cm,>1 cm from the skin, and ≤1 cm residual disease and no multicentric disease by magnetic resonance imaging were accrued to this institutional review board-approved study. Patients were randomized to laser versus radiofrequency ablation. The ultrasound-guided ablation was performed in the operating room and followed by immediate excision, whole-mount pathology with proliferating cell nuclear antigen staining, and reconstruction. Results: Twenty-one patients were enrolled onto the study. Fifteen patients received radiofrequency ablation, and all showed 100{\%} ablation and negative margins. Magnetic resonance imaging was helpful in excluding multicentric disease but less so in predicting presence or absence of residual disease. Seven of these patients showed no residual tumor and eight showed residual dead tumor (0.5 ± 0.7 cm, range 0.1-2.5 cm) at the biopsy site with clear margins. The laser arm (3 patients) pathology demonstrated unpredictability of the ablation zone and residual live tumor. Conclusions: This pilot study demonstrates the feasibility of a novel approach to minimally invasive therapy: percutaneous excision and effective cytoreduction, followed by radiofrequency ablation of margins for the treatment of breast cancer. Laser treatment requires further improvement.",
author = "Vicki Klimberg and Cristiano Boneti and Adkins, {Laura L.} and Maureen Smith and Eric Siegel and Vladimir Zharov and Scott Ferguson and Ronda Henry-Tillman and Brian Badgwell and Soheila Korourian",
year = "2011",
month = "10",
doi = "10.1245/s10434-011-2002-y",
language = "English (US)",
volume = "18",
pages = "3079--3087",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Feasibility of percutaneous excision followed by ablation for local control in breast cancer

AU - Klimberg, Vicki

AU - Boneti, Cristiano

AU - Adkins, Laura L.

AU - Smith, Maureen

AU - Siegel, Eric

AU - Zharov, Vladimir

AU - Ferguson, Scott

AU - Henry-Tillman, Ronda

AU - Badgwell, Brian

AU - Korourian, Soheila

PY - 2011/10

Y1 - 2011/10

N2 - Purpose: Percutaneous ablation of breast cancer has shown promise as a treatment alternative to open lumpectomy. We hypothesized that percutaneous removal of breast cancer followed by percutaneous ablation to sterilize and widen the margins would not only provide fresh naive tissue for tumor marker and research investigation, but also better achieve negative margins after ablation. Methods: Patients diagnosed by percutaneous biopsy (ultrasound or stereotactic-guided) with breast cancer ≥1.5 cm,>1 cm from the skin, and ≤1 cm residual disease and no multicentric disease by magnetic resonance imaging were accrued to this institutional review board-approved study. Patients were randomized to laser versus radiofrequency ablation. The ultrasound-guided ablation was performed in the operating room and followed by immediate excision, whole-mount pathology with proliferating cell nuclear antigen staining, and reconstruction. Results: Twenty-one patients were enrolled onto the study. Fifteen patients received radiofrequency ablation, and all showed 100% ablation and negative margins. Magnetic resonance imaging was helpful in excluding multicentric disease but less so in predicting presence or absence of residual disease. Seven of these patients showed no residual tumor and eight showed residual dead tumor (0.5 ± 0.7 cm, range 0.1-2.5 cm) at the biopsy site with clear margins. The laser arm (3 patients) pathology demonstrated unpredictability of the ablation zone and residual live tumor. Conclusions: This pilot study demonstrates the feasibility of a novel approach to minimally invasive therapy: percutaneous excision and effective cytoreduction, followed by radiofrequency ablation of margins for the treatment of breast cancer. Laser treatment requires further improvement.

AB - Purpose: Percutaneous ablation of breast cancer has shown promise as a treatment alternative to open lumpectomy. We hypothesized that percutaneous removal of breast cancer followed by percutaneous ablation to sterilize and widen the margins would not only provide fresh naive tissue for tumor marker and research investigation, but also better achieve negative margins after ablation. Methods: Patients diagnosed by percutaneous biopsy (ultrasound or stereotactic-guided) with breast cancer ≥1.5 cm,>1 cm from the skin, and ≤1 cm residual disease and no multicentric disease by magnetic resonance imaging were accrued to this institutional review board-approved study. Patients were randomized to laser versus radiofrequency ablation. The ultrasound-guided ablation was performed in the operating room and followed by immediate excision, whole-mount pathology with proliferating cell nuclear antigen staining, and reconstruction. Results: Twenty-one patients were enrolled onto the study. Fifteen patients received radiofrequency ablation, and all showed 100% ablation and negative margins. Magnetic resonance imaging was helpful in excluding multicentric disease but less so in predicting presence or absence of residual disease. Seven of these patients showed no residual tumor and eight showed residual dead tumor (0.5 ± 0.7 cm, range 0.1-2.5 cm) at the biopsy site with clear margins. The laser arm (3 patients) pathology demonstrated unpredictability of the ablation zone and residual live tumor. Conclusions: This pilot study demonstrates the feasibility of a novel approach to minimally invasive therapy: percutaneous excision and effective cytoreduction, followed by radiofrequency ablation of margins for the treatment of breast cancer. Laser treatment requires further improvement.

UR - http://www.scopus.com/inward/record.url?scp=83055188140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055188140&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-2002-y

DO - 10.1245/s10434-011-2002-y

M3 - Article

C2 - 21904959

AN - SCOPUS:83055188140

VL - 18

SP - 3079

EP - 3087

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -